

Functional polymorphisms within the inflammatory pathway regulate expression of extracellular matrix components in a genetic risk dependent model for anterior cruciate ligament injuries

Mathijs A.M. Suijkerbuijk^{a*}, Marco Ponzetti^{b*}, Masouda Rahim^c, Michael Posthumus^c, Charlotte K. Häger^d, Evalena Stattin^e, Kjell G. Nilsson^f, Anna Teti^b, Duncan E. Meuffels^a, Bram J.C. van der Eerden^g, Malcolm Collins^c, Alison V. September^c

^a Department of Orthopaedic Surgery, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands,

^b Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Camponeschi, 19, 67100, L'Aquila, Italy

^c Division of Exercise Science and Sports Medicine, Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town 7935, South Africa

^d Department of Community Medicine and Rehabilitation, Umeå University, 90187, Umeå, Sweden

^e Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 75236, Uppsala, Sweden

^f Department of Surgical and Perioperative Sciences, Umeå University, Umeå, 90187, Sweden

^g Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands,

* Both authors contributed equally to this work

Corresponding Author

Alison V. September

Division of Exercise Science and Sports Medicine

Department of Human Biology, The University of Cape Town

3rd Floor SSISA building

Boundary Road

Newlands, 7700

Cape Town, South Africa

Tel: +27 21 650 4559, Fax: +27 21 650 1796

E-mail: alison.september@uct.ac.za

Abstract: 250/250 words

Main text: 2961/3000 words

Number of Tables: 1

Number of Figures: 2

References: 30/30

Abstract

Objectives: To investigate the functional effect of genetic polymorphisms of the inflammatory pathway on structural extracellular matrix components (ECM) and the susceptibility to an anterior cruciate ligament (ACL) injury.

Design: Laboratory study, case-control study

Method: Eight healthy participants were genotyped for interleukin (*IL*) *1B* rs16944 C>T and *IL6* rs1800795 G>C and classified into genetic risk profile groups. Differences in type I collagen (*COL1A1*), type V collagen (*COL5A1*), biglycan (*BGN*) and decorin (*DCN*) gene expression were measured in fibroblasts either unstimulated or following IL-1 β , IL-6 or tumor necrosis factor (TNF)- α treatment.

Moreover, a genetic association study was conducted in: (i) a Swedish cohort comprised of 116 asymptomatic controls (CON) and 79 ACL ruptures and (ii) a South African cohort of 100 CONs and 98 ACLs. Participants were genotyped for *COL5A1* rs12722 C>T, *IL1B* rs16944 C>T, *IL6* rs1800795 G>C and *IL6R* rs2228145 G>C.

Results: *IL1B* high-risk fibroblasts had decreased *BGN* ($p=0.020$) and *COL5A1* ($p=0.012$) levels after IL-1 β stimulation and expressed less *COL5A1* ($p=0.042$) following TNF- α treatment. Similarly, unstimulated *IL6* high-risk fibroblasts had lower *COL5A1* ($p=0.012$) levels than *IL6* low-risk fibroblasts.

In the genetic association study, the *COL5A1-IL1B-IL6* T-C-G ($p=0.034$, Haplo-score 2.1) and the *COL5A1-IL1B-IL6R* T-C-A ($p=0.044$, Haplo-score: 2.0) combinations were associated with an increased susceptibility to ACL injury in the Swedish cohort when only male participants were evaluated.

Conclusion: This study shows that polymorphisms within genes of the inflammatory pathway modulate the expression of structural and fibril-associated ECM components in a genetic risk depended manner, contributing to an increased susceptibility to ACL injuries.

Key words

1. Anterior cruciate ligament injury
2. Extracellular matrix
3. Genetics
4. Polymorphisms
5. Personalized Medicine

Introduction

One of the most common knee injuries include the anterior cruciate ligament (ACL) rupture. The ability of the ACL to maintain its extracellular matrix (ECM) integrity is critical to its function to effectively resist mechanical loads and prevent injury¹. Loading activates matrix-remodeling pathways to maintain ECM homeostasis, such as the inflammatory pathways (**Figure 1**). Therefore, it is not surprising that polymorphisms within these pathways contribute to the susceptibility of ACL injuries^{2,3}.

Type V collagen is a functionally important collagen for the maintenance of tissue structure and integrity. The major isoforms consists of two $\alpha 1$ (V) and one $\alpha 2$ (V) chains encoded by *COL5A1* and *COL5A2* respectively⁴. Polymorphisms within the 3'UTR of *COL5A1* were previously implicated in ACL rupture^{5,6} and tendinopathy^{5,7}. In addition, polymorphisms within genes encoding the $\alpha 1(I)$ chain of type I collagen (*COL1A1*)⁸, biglycan (*BGM*)⁹ and decorin (*DCN*)⁹ were associated with ACL injury susceptibility. Together, these molecules form the basic building blocks of the ECM and are involved in collagen fibrillogenesis.

Interleukin (IL) -1 β is a pro-inflammatory cytokine encoded by *IL1B* and up-regulates the production of matrix metalloproteinases, regulating the degradation of specific ECM components, such as collagen types V and X^{10,11}. In addition, IL-1 β induces its own expression and the expression of other pro-inflammatory cytokines such IL-6 (**Figure 1**)¹¹. The C-allele of the *IL1B* promoter polymorphism rs16944 C>T increases IL-1 β mRNA expression levels¹² and is hypothesised to increase susceptibility to tendinopathy and ACL injury^{13,14}.

IL6 is known to induce apoptosis¹⁵ and increase *IL6* gene expression as seen with the G-allele of the *IL6* rs1800795 G>C polymorphism¹⁶, would potentially be associated with increased risk for ligament injuries. IL-6 needs to bind and form complexes with the interleukin-6 receptor (IL-6R) in order to exert its biological function. IL-6R exists as two isoforms: a membrane-bound receptor and a soluble receptor. *IL6R* rs2228145 A>C is located in the cleavage site and is thought to affect cleavage efficiency. Therefore, we hypothesize that the *IL6R* rs2228145 AA genotype is associated with an increased susceptibility to ligament injury.

Although currently no genetic loci within the gene encoding tumor necrosis factor α (TNF- α) have been associated with either ACL injuries or tendinopathies, this pro-inflammatory protein is considered to be key in the inflammatory pathway¹⁷. The biological function of TNF- α is executed after binding to its receptor, the tumor necrosis factor receptor superfamily member 1A (TNFRSF1A). Similar to IL-6, TNF- α is involved in apoptosis and thereby possibly contributes to matrix remodeling capacity¹⁷.

The main aim of the current study was to investigate the effects of specific genetic loci within the inflammatory pathway on the production of ECM components in an injury risk model. Additionally, the association of these genetic loci with susceptibility to ACL injury was evaluated in two independent populations of different ancestry. Based on the *a priori hypothesis* it was proposed that the *IL1B* rs16944 CC and the *IL6* rs1800795 GG downregulate the production of ECM components and should therefore be associated with an increased susceptibility to ligament injuries.

Methods

All participants completed questionnaires regarding personal details, medical history, sporting history and a family history of tendon and ligament injury. Written informed consent was obtained from all participants according to the Declaration of Helsinki. Ethics approval was attained from the Human Research Ethics Commission (HREC) of Faculty of Health Sciences, University of Cape Town, South Africa (HREC 164/2006 and 645/2014) and the Regional Ethical Review Board in Umeå, Sweden (dnr. 2011-200-31M), where relevant.

Participants

In vitro study: Eight healthy, unrelated South African participants of self-reported Caucasian ancestry with no history of musculoskeletal soft tissue injuries were recruited. Venous blood and skin biopsies were taken from each participant.

Swedish cohort: 195 physically active and unrelated participants (age 19-65 years) were recruited between 2011 and 2013 from either the Västerbotten or Norrbotten regions of Sweden, via the orthopedic clinics in two major hospitals in the cities of Umeå: Västerbotten

and Luleå: Norrbotten. Majority participants were recruited from a long term follow up of ACL injury¹⁸. This cohort consisted of 79 participants with ACL rupture (SWE-ACL) and 116 asymptomatic participants without any history of ACL or tendon injury (SWE-CON). ACL ruptures were diagnosed based on physical examination, magnetic resonance imaging and arthroscopically confirmed at the University hospital in Umeå. Mechanism of injury data was categorized into direct contact, indirect contact, non-contact and skiing sports as previously defined⁶. All 79 cases reported a non-contact mechanism (SWE-NON) of injury.

South African cohort: 198 physical active and unrelated participants were recruited from South Africa as previously described¹⁹. This cohort comprised of 100 asymptomatic controls (SA CON) and 98 participants with an ACL rupture (SA ACL) of which 51 reported a non-contact mechanism of injury.

Genotyping

A previously described protocol with slight modifications²⁰ was used to extract genomic DNA from venous blood. Participants participating in the *in vitro* study were genotyped for the *IL1B* rs16944 C>T and *IL6* rs1800795 G>C polymorphisms. Restriction fragment length polymorphism (RFLP) analysis was used for *IL1B* rs16944 (*AvaI*)¹⁴ while custom designed fluorescence-based Taqman PCR assays (Applied Biosystems, Foster City, CA, USA) were used to genotype *IL6* rs1800795. Based on their genotypes, participants were either classified in the high-risk or low-risk profile group.

Participants for the genetic association study were additionally screened for *COL5A1* rs12722 C>T and *IL6R* rs2228145 A>C. All samples in the Swedish (n=195) and the South African cohort (n=198) were genotyped for the four SNPs using standard genotyping protocols. Restriction fragment length polymorphism (RFLP) analysis was used for the *COL5A1* rs12722 (*Bstul*), and *IL6R* rs2228145 (*HindIII*) SNPs. All single nucleotide polymorphisms (SNPs): *COL5A1* rs12722 C>T, *IL1B* rs16944 C>T, *IL6* rs1800795 G>C and

IL6R rs2228145 A>C were selected based on their previously reported genetic associations with risk of ACL ruptures and Achilles tendinopathy^{2, 3}.

Fibroblast culture and treatment

To establish primary fibroblast cultures, skin biopsies were processed according to a modified Baumgarten protocol²¹. Human dermal fibroblasts were cultured to 70% confluency in Dulbecco's modified Eagle medium (DMEM, Gibco, Carlsbad, CA, USA) with 200 units/mL penicillin, 100 µg/mL streptomycin, 3.97 mM GlutaMAX (Gibco) and 10% FBS. Cells were serum-starved for 8h in DMEM and subsequently treated with 10ng/ml human recombinant (hr) IL6²², 20ng/ml hrIL-1β²³ or 10ng/ml hrTNF-α²² (all from Peprotech, Rocky Hills, NJ, USA). After 24h, cells were washed twice in ice-cold Dulbecco's phosphate-buffered saline (DPBS, Sigma-Aldrich, Saint Louis, Missouri, USA) and frozen at -80°C until ready for RNA extraction, using the RNeasy kit (Qiagen, Venlo, The Netherlands). Subsequently, a cDNA synthesis kit including a recombinant RNase inhibitor (Thermo Scientific) using oligo (dT)s as primers was used.

Real time RT-PCR

A SYBR green-based buffer (Thermo Scientific), 10ng of cDNA, and primers specific for the transcript of interest, to a final concentration of 500nM each were mixed. PCR cycles were as follows: (2'30" at 50°C: 2'30" at 95°C) X1, (15" at 95°C: 30" at 60°C) X50 followed by melt-curve analysis (95°C-60°C-95°C). Real time RT-PCR analyses were performed using a Quantstudio3 real-time PCR machine (Thermo Scientific). The mRNA expression levels of structural matrix components, such as *COL5A1*, *COL1A1*, *DCN* and *BGN* were assessed for each sample including components of the inflammatory pathway, namely *IL1B*, *IL6R1*, *IL6*, *IL6R* and *TNFRSF1A* (Invitrogen, Carlsbad, CA, USA) (**Supplementary Table 1**). Cofilin (Invitrogen) was previously found stable and linearly correlated with RNA quantity (data not shown), and was therefore used as the housekeeping gene.

Statistics

Statistical analyses were performed with the programming environment R (R Development Core Team). In the cytokine stimulation experiments, statistics were performed using Unpaired, two-tailed Student's t-test. Power analysis was performed using QUANTO v.1.2.4 (<http://biostats.usc.edu/software>) to calculate sample size for the Swedish cohort. Assuming minor allele frequencies between 0.1 and 0.5 a sample size of 79 cases would be adequate to detect an allelic odds ratio (OR) of 2.3 and greater at a power of 80%. Basic descriptive statistics were compared using the one-way analysis of variance to detect significant differences between characteristics of the SWE-CON group and the SWE-NON group. The R package *genetics*²⁴ and *SNPassoc*²⁵ were used to analyse differences in genotype and allele frequencies between the groups and to calculate Hardy-Weinberg equilibrium probabilities. Inferred allele constructs were created for *COL5A1-IL1B-IL6-IL6R* genes from both the Swedish and South African genotype data respectively using the *haplo.stats* package in R²⁶. The analysed models were based on previously reported associations^{13, 14}.

Results

Basal mRNA levels of high-risk vs. low-risk fibroblasts

Fibroblasts derived from 8 donors had a high-risk genetic profile for either *IL1B* rs16944 C>T or *IL6* rs1800795 G>C (**Supplementary Table 2**). All other donors who did not meet these two genetic risk profiles were excluded from further analysis. No significant differences in basal expression were observed in any of the ECM genes when fibroblasts were classified based on *IL1B* genotypes (**Figure 2A**). A reduced ($p=0.012$) *COL5A1* expression was noted in *IL6*-high-risk fibroblasts compared to low-risk fibroblasts. As for the cytokine-related genes, we found that *TNFRSF1A* was less ($p=0.003$) expressed in the untreated *IL6*-high-risk fibroblasts. (**Supplementary Figure 1A, B**).

Response to cytokine stimulation by high-risk vs. low-risk fibroblasts

In *IL1B*-high-risk fibroblasts, *COL5A1* ($p=0.012$) and *BGN* ($p=0.020$) expression were reduced following hrIL-1 β . Additionally, treatment with hrTNF- α resulted in decreased *COL5A1* ($p=0.042$) levels (**Figure 2C**). In untreated IL6 high-risk fibroblasts, *COL5A1* was reduced ($p=0.012$) compared to IL6 low-risk fibroblasts (**Figure 2B**). No Stimulation of the fibroblasts with hrIL-6 (**Supplementary Figure 1C, D**), hrIL-1 β (**Supplementary Figure 1E, F**) or hrTNF- α (**Supplementary Figure 1G, H**) did not significantly alter the expression of any of the cytokine-related genes analysed.

Case control genetic association study

Polymorphisms within *IL1B* and *IL6* alter the expression of structural and fibril-associated ECM components and herewith possibly modulate the susceptibility of ligament injuries. Therefore, these associations were further investigated in other population groups from (i) Sweden and (ii) an indigenous mixed ancestry population from South Africa.

Participants

The South African population was previously described in detail¹⁹. Swedish participants were matched for height, body mass and body mass index (BMI) (**Supplementary Table 3**). However, participants in the SWE-CON group consisted of significantly less men (34.5%, $n=40$) than the SWE-NON group (54.4%, $n=43$, $p=0.014$) and were significantly older (44.7 ± 11.9 , $n=114$) than participants in the SWE-NON group (36.5 ± 13.7 , $n=78$, $p<0.001$). Differences in medical and family history are displayed in **Supplementary Table 4**. No significant genotype effects were noted on age, sex, height, body mass or body mass index for the investigated polymorphisms (**Supplementary Table 5**).

Genotype and allele frequency distributions

No significant differences in genotype or allele frequency distributions were observed for either *COL5A1* rs12722 C>T, *IL1B* rs16944 C>T and *IL6* rs1800795 G>C in both the South African and Swedish cohorts (**Table 1**). However, for the South African cohort the *IL6R* rs2228145 A>C CC genotype was significantly overrepresented ($p=0.028$) in the SA-CON group (13%, $n=12$) compared to the SA-ACL group (3%, $n=3$). Although not significant ($p=0.054$), a similar trend was observed when comparing the SA-CON group (13%, $n=12$) to the SA-NON subgroup (11%, $n=6$). Furthermore, the genotype and allele frequency distributions significantly differed between the South African and Swedish cohorts (**Supplementary Table 6**) for all the polymorphisms tested. Therefore, cohorts could not be combined for further analysis.

Frequency distributions of allele combinations

Allele combinations were inferred for *COL5A1-IL1B-IL6* and *COL5A1-IL1B-IL6R*. For each of the two allele combinations, eight possible constructs were inferred at a frequency above 4%. For the South African cohort, no significant differences in the frequency distributions of these combinations were observed when all participants were evaluated or when only male or only female participants were compared (**Supplementary Figure 2**).

The frequency distributions for the *COL5A1-IL1B-IL6* and the *COL5A1-IL1B-IL6R* allele combinations were similar between the control and cases when all participants or only the female participants in the Swedish cohort were compared (**Supplementary figures 3A and 3C**). However, for the *COL5A1-IL1B-IL6* allele combination, when only males participants were evaluated, the T-C-G combination was significantly underrepresented ($p=0.034$ Haplo-score: 2.1) in the SWE-CON (7.7%, $n=3$) compared to the SWE-NON (18.0%, $n=8$) group (**Supplementary Figure 3B**). Furthermore, the frequency distributions for the *COL5A1-IL1B-IL6R* allele combinations, showed the T-C-A combination to be significantly underrepresented

($p=0.044$, Haplo-score: 2.0) in the SWE-CON (28.0%, $n=11$) compared to the SWE-NON (14.0%, $n=6$) group when only the male participants were compared in the Swedish cohort.

Discussion

Considering the ligament as an integrative part of the knee joint, it is plausible that the ACL is subjected to cues derived from its surrounding anatomical structures, such as the synovium or synovial fluid. It is proposed, that as a response to repetitive mechanical overloading, macrophages might infiltrate tissues surrounding the ligaments²⁷. Thereby, potentially exposes the ligamentocytes to an additional amount of specific inflammatory cytokines as part of the matrix remodeling mechanism. It is interesting, that some of the genetic susceptibility loci implicated in tendon and ligament injuries encode proteins involved in the homeostatic regulation of ECM components of both tendon and ligament, and components of the proinflammatory pathway^{2, 3}. This study therefore, used a hypothesis-based approach to evaluate the potential impact of the inflammatory pathway on modulating susceptibility to ligament injuries using an *in vitro* risk associated model, complimented with a genetic association approach.

For the functional *IL1B* rs16944 polymorphism, treatment with hrIL- β resulted in a 1.3-fold decrease ($p=0.020$) of *BGN* and a 2.1-fold ($p=0.012$) decrease of *COL5A1* in a genetic risk associated dependent manner. In addition, hrTNF- α treatment displayed a 2.0-fold ($p=0.042$) reduction in *COL5A1* mRNA levels in the fibroblasts with an *IL1B* rs16944 CC genotype. We suggest that, given an inflammatory micro-environment where these cytokines are abundant, matrix production is differently affected in *IL1B*-high risk compared to *IL1B*-low risk genetic profiles.

The *IL6* rs1800795 G-allele increases IL-6 mRNA expression levels, inducing apoptosis¹⁵ which might decrease the production of ECM components. Our experiments indirectly support this hypothesis since fibroblasts having the *IL6* rs1800795 GG genotype displayed a 2.8-fold reduction ($p=0.012$) in *COL5A1* mRNA. Although not significant, a similar

trend was observed for other associated ECM components such as *DCN*. This is an important finding, since both *COL5A1* and *DCN* are required for normal fibrillogenesis²⁸.

At basal levels, the expression of pro-inflammatory genes was relatively low for all groups. However, with the exception of *TNFRSFA1* mRNA expression, mRNA levels of all the investigated cytokines were increased on average between 1.03 and 6109 fold in all the groups after treatment with hrIL-1 β (**Supplementary Figure 1C, D**), hrIL-6 (**Supplementary Figure 1E, F**) and TNF- α (**Supplementary Figure 1G, H**). More specifically, treatment with hrIL-1 β significantly upregulated *IL1B* and *IL6* mRNA levels 3690 and 3948 fold respectively, although no statistically significant differences in their expression were noted between the high- and low-risk groups. This is in agreement with the hypothesis as shown in **Figure 1** and with previous work.

These results support the proposal that polymorphisms within *IL1B* and *IL6* alter the expression of structural and fibril-associated ECM components and herewith possibly modulate the susceptibility to ligament injuries. This holds true in specific cohorts where these loci were implicated in risk models for the susceptibility to tendon and ligament injuries^{13, 14}. These associations were therefore evaluated in two independent population groups from different ancestries, one from Sweden and the other from South Africa in an attempt to identify the susceptibility significance of these genetic loci in different populations.

In the South African cohort, the *IL6R* rs2228145 CC genotype was significantly overrepresented ($p=0.028$) in the controls, compared to individuals that sustained an ACL injury. Although the CC genotype frequencies appeared to be similar in our Swedish cohort and in a previously reported South African Caucasian cohort¹³, it did not reach the level of significance. As shown previously, the *COL5A1-IL1B-IL6* T-C-G and the *COL5A1-IL1B-IL6R* T-C-A allele combinations were found to be associated with an increased susceptibility to sustain an ACL rupture in the Swedish cohort when only male participants were evaluated^{13, 14}. These associations were not reproduced in the South African cohort evaluated in this study, which might be explained by the different genetic background of the cohorts, as illustrated by the significant differences in genotype frequencies.

It becomes evident that a finely balanced inflammatory response is required for remodeling of the ECM²⁹ and that genetic polymorphisms potentially affect the production of inflammatory cytokines^{12, 16}. The specific identity of these biological key role players however still remain unknown, including the threshold number and the time course of when they are required to direct the remodeling process within tendon and ligament. Therefore, future research should focus on the identification and quantification of inflammatory factors and on their time courses in tendon and ligament injuries. This may provide insights for biology-based therapies, such as anti-cytokine antibodies or cytokine antagonists and the most effective treatment period. Another approach might be to target cells that are responsible for the production of inflammatory cytokines, such as macrophages.

The *in vitro* experiments used dermal fibroblasts of eight individuals. Although dermal fibroblasts might have similar characteristics as tenocytes or ligamentocytes, their function and exact composition differ, possibly influencing their response to stimuli. In addition, a tissue-specific culture model applying a tensile force is required to study the effect of polymorphisms on matrix remodeling in more detail. Future research should aim to increase the number of donors. The difference in sex distribution in the genetic association study is explained by the fact that females participate less frequently in pivoting sports and therefore males and females were both tested together and separately for potential genetic associations with susceptibility for ACL injury.

In conclusion, this study describes specific polymorphisms within the inflammatory pathway to modulate the synthesis and degradation of structural and fibril-associated ECM components and thereby potentially contributing to an increased susceptibility to ACL injuries. This provisional evidence improves our understanding of the underlying mechanism for the genetic susceptibility to ACL ruptures and might lead to early identification of individuals who are of increased susceptibility to ACL injury and the potential application of personalized preventive or therapeutic interventions.

Practical implications

- Given an inflammatory micro-environment where cytokines are abundant, matrix production is differentially affected in an *IL1B* genetic risk dependent manner
- The work improves the understanding of how polymorphisms within the inflammatory signaling pathway modulate the susceptibility of ACL injuries
- This knowledge contributes to the identification of potential therapeutic targets to reduce ACL injury and to enhance healing.

Acknowledgements

The authors would like to thank Prof. Dr. G.J.V.M. van Osch for her contribution to the study design and data interpretation. In addition, we are grateful to Dr. C. D'Alton and Dr. M. Nel for taking the skin biopsies.

This research was funded in part by funds from the National Research Foundation of South Africa grant CPRR 106068 and the University of Cape Town Research Council, South Africa. M.A.M.S and M.P. were financially supported by the European Union funded project RUBICON H2020-MSCA-RISE-2015 – 690850. MR was funded by the Harry Crossley Postdoctoral fellowship. In Sweden, financial support was obtained from the Swedish Scientific Research Council (Grants No. K2011-69X-21877-01-6, K2014-99X-21876-04-4), Västerbotten County Council (Grant No. ALF VLL548501 and Strategic funding VLL-358901; Project No. 7002795).

References

1. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. *Disease models & mechanisms*. 2011; 4(2):165-178.
2. Rahim M, Collins M, September A. Genes and Musculoskeletal Soft-Tissue Injuries. *Medicine and sport science*. 2016; 61:68-91.
3. September A, Rahim M, Collins M. Towards an Understanding of the Genetics of Tendinopathy. *Advances in experimental medicine and biology*. 2016; 920:109-116.
4. Malfait F, Wenstrup RJ, De Paepe A. Clinical and genetic aspects of Ehlers-Danlos syndrome, classic type. *Genetics in medicine : official journal of the American College of Medical Genetics*. 2010; 12(10):597-605.
5. Collins M, Posthumus M. Type V collagen genotype and exercise-related phenotype relationships: a novel hypothesis. *Exercise and sport sciences reviews*. 2011; 39(4):191-198.

6. Posthumus M, September AV, O'Cuinneagain D, van der Merwe W, Schwellnus MP, Collins M. The COL5A1 gene is associated with increased risk of anterior cruciate ligament ruptures in female participants. *The American journal of sports medicine*. 2009; 37(11):2234-2240.
7. September AV, Cook J, Handley CJ, van der Merwe L, Schwellnus MP, Collins M. Variants within the COL5A1 gene are associated with Achilles tendinopathy in two populations. *British journal of sports medicine*. 2009; 43(5):357-365.
8. Posthumus M, September AV, Keegan M, et al. Genetic risk factors for anterior cruciate ligament ruptures: COL1A1 gene variant. *British journal of sports medicine*. 2009; 43(5):352-356.
9. Mannion S, Mtintsilana A, Posthumus M, et al. Genes encoding proteoglycans are associated with the risk of anterior cruciate ligament ruptures. *British journal of sports medicine*. 2014; 48(22):1640-1646.
10. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. *Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists*. 1993; 4(2):197-250.
11. Tsuzaki M, Guyton G, Garrett W, et al. IL-1 beta induces COX2, MMP-1, -3 and -13, ADAMTS-4, IL-1 beta and IL-6 in human tendon cells. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. 2003; 21(2):256-264.
12. Landvik NE, Hart K, Skaug V, Stangeland LB, Haugen A, Zienolddiny S. A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer. *Carcinogenesis*. 2009; 30(7):1186-1192.
13. Rahim M, Mannion S, Klug B, et al. Modulators of the extracellular matrix and risk of anterior cruciate ligament ruptures. *Journal of science and medicine in sport*. 2017; 20(2):152-158.
14. September AV, Nell EM, O'Connell K, et al. A pathway-based approach investigating the genes encoding interleukin-1beta, interleukin-6 and the interleukin-1 receptor

- antagonist provides new insight into the genetic susceptibility of Achilles tendinopathy. *British journal of sports medicine*. 2011; 45(13):1040-1047.
15. Millar NL, Wei AQ, Molloy TJ, Bonar F, Murrell GA. Cytokines and apoptosis in supraspinatus tendinopathy. *The Journal of bone and joint surgery. British volume*. 2009; 91(3):417-424.
 16. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. *The Journal of clinical investigation*. 1998; 102(7):1369-1376.
 17. Qidwai T, Khan F. Tumour necrosis factor gene polymorphism and disease prevalence. *Scandinavian journal of immunology*. 2011; 74(6):522-547.
 18. Tengman E, Brax Olofsson L, Nilsson KG, Tegner Y, Lundgren L, Hager CK. Anterior cruciate ligament injury after more than 20 years: I. Physical activity level and knee function. *Scandinavian journal of medicine & science in sports*. 2014; 24(6):e491-500.
 19. Rahim M, Hobbs H, van der Merwe W, Posthumus M, Collins M, September AV. Investigation of angiogenesis genes with anterior cruciate ligament rupture risk in a South African population. *Journal of sports sciences*. 2018; 36(5):551-557.
 20. Mokone GG, Schwellnus MP, Noakes TD, Collins M. The COL5A1 gene and Achilles tendon pathology. *Scandinavian journal of medicine & science in sports*. 2006; 16(1):19-26.
 21. Baumgarten IM. A comparison of metabolic pathway dynamics in man and other mammals [Internet]. 1993. Available from: <http://digitalknowledge.cput.ac.za:8081/xmlui/handle/11189/796>. Accessed 2018 Nov 2.
 22. John T, Lodka D, Kohl B, et al. Effect of pro-inflammatory and immunoregulatory cytokines on human tenocytes. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. 2010; 28(8):1071-1077.

23. de Mos M, Joosten LA, Oppers-Walgreen B, et al. Tendon degeneration is not mediated by regulation of Toll-like receptors 2 and 4 in human tenocytes. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. 2009; 27(8):1043-1047.
24. Warnes G. Genetics: A package for population genetics. : R package (version 1.3.6); 2011.
25. Gonzalez JR, Armengol L, Sole X, et al. SNPassoc: an R package to perform whole genome association studies. *Bioinformatics (Oxford, England)*. 2007; 23(5):644-645.
26. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. *American journal of human genetics*. 2002; 70(2):425-434.
27. Wu P, Holguin N, Silva MJ, Fu M, Liao W, Sandell LJ. Early response of mouse joint tissue to noninvasive knee injury suggests treatment targets. *Arthritis & rheumatology (Hoboken, N.J.)*. 2014; 66(5):1256-1265.
28. Lieberthal J, Sambamurthy N, Scanzello CR. Inflammation in joint injury and post-traumatic osteoarthritis. *Osteoarthritis and cartilage*. 2015; 23(11):1825-1834.
29. Dakin SG, Dudhia J, Smith RK. Resolving an inflammatory concept: the importance of inflammation and resolution in tendinopathy. *Veterinary immunology and immunopathology*. 2014; 158(3-4):121-127.
30. Chan KM, Fu SC, Wong YP, Hui WC, Cheuk YC, Wong MW. Expression of transforming growth factor beta isoforms and their roles in tendon healing. *Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society*. 2008; 16(3):399-407.

Table 1. Genotype and minor allele frequency distributions, and p-values for Hardy-Weinberg exact test for the four selected polymorphisms in the control (SWE-CON and SA-CON), the anterior cruciate ligament (SA-ACL) rupture group and ACL subgroup with a noncontact (SWE-NON, and SA-NON) mechanism of injury within the South African and Swedish cohorts.

		South Africa				Sweden			
		SA-CON	SA-ACL	p-value ¹	SA-NON	p-value ²	SWE-CON	SWE-NON	p-value ²
COL5A1 rs12722 C > T	n	96	93		48		109	77	
	CC	37 (36)	27 (25)	0.866	35 (17)	0.793	22 (24)	23 (18)	0.773
	CT	49 (47)	52 (48)		54 (26)		43 (47)	47 (36)	
	TT	14 (13)	22 (20)		10 (5)		35 (38)	30 (23)	
	T allele	38 (73)	47 (88)	0.851	38 (36)	1.000	56 (123)	53 (82)	0.617
	HWE	0.829	0.824		0.367		0.241	0.648	
IL1B rs16944 C > T	n	98	93		48		112	78	
	CC	24 (24)	27 (25)	0.530	27 (13)	0.923	39 (44)	44 (34)	0.799
	CT	47 (46)	52 (48)		44 (21)		41 (46)	40 (31)	
	TT	29 (28)	22 (20)		29 (14)		20 (22)	17 (13)	
	T allele	52 (102)	47 (88)	0.411	51 (49)	0.971	40 (90)	37 (57)	0.542
	HWE	0.549	0.836		0.395		0.120	0.224	
IL6 rs1800795 G > C	n	98	98		51		113	77	
	GG	72 (71)	64 (63)	0.445	67 (34)	0.339	22 (25)	26 (20)	0.606
	GC	26 (25)	31 (30)		27 (14)		59 (67)	52 (40)	
	CC	2 (2)	5 (5)		6 (3)		19 (21)	22 (17)	
	C allele	15 (29)	20 (40)	0.185	20 (20)	0.369	48 (109)	48 (74)	1.000
	HWE	1.000	0.539		0.373		0.060	0.821	
IL6R rs2228145 A > C	n	95	95		49		112	76	
	AA	54 (51)	58 (55)	0.028	55 (27)	0.054	53 (59)	46 (35)	0.618
	AC	34 (32)	39 (37)		43 (21)		37 (41)	46 (35)	
	CC	13 (12)	3 (3)		2 (1)		11 (12)	8 (6)	
	C allele	29 (56)	23 (43)	0.161	23 (23)	0.346	29 (65)	31 (47)	0.779
	HWE	0.082	0.385		0.257		0.253	0.599	

Genotype and allele frequencies are expressed as a percentage with the number of participants (n) in parentheses. ¹ CON vs. ACL (unadjusted p-value), ² CON vs. NON (unadjusted p-value). P-values in bold typeset indicate significance ($p < 0.050$)

Figure 1: Schematic representation of the proposed downstream effects of cytokines IL-1 β and IL-6 which are upregulated in response to mechanical loading of a ligament

13-15, 30

Activation/upregulation is represented by a pointed arrow head (\rightarrow) and inhibition/down regulation is represented by a perpendicular line at the end (\perp). The boxed molecules are the ones investigated in the current study. Abbreviations: ECM, extracellular matrix; IL-1 β , interleukin-1 β ; IL-6, interleukin-6; IL-6R, interleukin-6 receptor; MMPs, matrix metalloproteinases; ROS, reactive oxygen species; TGF- β , transforming growth factor β ; TNF- α , tumor necrosis factor

Figure 2: mRNA expression of extracellular matrix genes in stimulated and unstimulated fibroblasts. Primary human fibroblasts were obtained from 8 healthy volunteers and classified in high risk or low risk for ligament injuries based on *IL1B* rs12722 C>T (A, C, E, G) and *IL6* rs1800795 G>C (B, D, F, H). Fibroblasts were treated with vehicle (PBS) to evaluate basal levels (A, B) or hr-IL-6 (C, D), hrIL-1 β (E, F) or hrTNF- α (G, H) to evaluate fold-response to the treatment, compared to vehicle of the expression of extracellular matrix genes type I collagen α 1 (*COL1A1*), type V collagen α 1 (*COL5A1*), decorin (*DCN*), biglycan (*BGN*). Data is presented as (A, B) $2^{-\Delta Ct}$ to assess gene expression compared to *CFL1* (housekeeping gene) or (C-H) fold to vehicle (dotted lines). Data is presented as mean with standard deviation (SD). Unpaired two-tailed Student's *t*-test. P-values in bold typeset indicate significance ($p < 0.050$)




Figure 1

Supplementary Table 1. Primers used for RT-PCR analysis

Gene	Forward primer (5' → 3')	Reverse primer (5' → 3')
<i>COL5A1</i>	GACAAGAAGTCCGAAGGGGC	TAGGAGAGCAGTTTCCCACG
<i>COL1A1</i>	TGAAGGGACACAGAGGTTTCAG	GTAGCACCATCATTTCACGA
<i>DCN</i>	CAGACCAAGCACGCAAACA	TCACAACCAGGGAACCTTGC
<i>BGN</i>	CACCGGACAGATAGACGTGC	CATGGCGGATGGACCTGGAG
<i>IL6</i>	GGATTCAATGAGGAGACTTGCC	GGGTCAGGGGTGGTTATTGC
<i>IL1B</i>	TTGCTCAAGTGTCTGAAGCAGC	CTTGCTGTAGTGGTGGTCGG
<i>IL6R</i>	CACGCCTTGGACAGAATCCA	TCCAGCAACCAGGAATGTGG
<i>IL1R1</i>	GGTAGACGCACCCTCTGAAG	GCATTTATCAGCCTCCAGAGAAGA
<i>TNFRSFA1</i>	ATTGGACTGGTCCCTCACCT	GTAGGTTCCCTTTGTGGCACTT
<i>CFL1</i>	ATAAGGACTGCCGCTATGCC	CGGGGGCCCAGAAGATAAAC

Supplementary Table 2. Genetic risk profiles of the participants based on their (A) *IL1B* rs16944 C>T and (B) *IL6* rs1800795

G>C genotypes.

A.

	Participant ID	<i>IL1B</i> rs16944	Sex
Low risk	5	CT	F
	7	CT	M
	8	CT	F
	11	CT	M
	22	TT	M
High risk	3	CC	M
	10	CC	M
	24	CC	F

B.

	Participant ID	<i>IL6</i> rs1800795	Sex
Low risk	3	CC	M
	5	GC	F
	22	GC	M
	24	GC	F
	7	GG	M
High risk	8	GG	F
	10	GG	M
	11	GG	M

M, male; F, female

Supplementary Table 3. Patient characteristics of the control (SWE-CON) group and the anterior cruciate ligament group with a noncontact (SWE-NON) mechanism of injury in a Swedish cohort

	SWE-CON (n=116)	SWE-NON (n=79)	p-value
Age (years) ¹	44.7 ± 11.9 (114)	36.5 ± 13.7 (78)	<0.001
Sex (% male)	34.5 (116)	54.4 (79)	0.014
Height (cm)	172.3 ± 10.1 (108)	173.4 ± 8.6 (71)	0.438
Body mass (kg) ¹	72.1 ± 13.6 (107)	75.0 ± 12.8 (71)	0.149
Body mass index (kg/m ²) ¹	24.4 ± 2.9 (107)	24.7 ± 2.9 (70)	0.466

Values are presented as mean ± standard deviations except for sex, which is expressed as a percentage. The number of participants (n) with available data for each variable is in parenthesis.

¹Self-reported values at the time of recruitment for the SWE-CON group, and at time of ACL rupture for the SWE-NON group.

Supplementary Table 4. Medical history and family injury for the control (SWE-CON) and non-contact (SWE-NON) anterior cruciate ligament rupture group of the Swedish cohort

	Male			Female			p-value ²
	SWE-CON (n= 40)	SWE-NON (n= 42)	p-value ¹	SWE-CON (n= 76)	SWE-NON (n= 37)	p-value ¹	
Previous ligament injury	88.6 (35)	100.0 (35)	0.114	73.5 (68)	81.8 (33)	0.458	0.035
Previous joint injury	35.1 (37)	51.3 (39)	0.235	37.5 (72)	41.7 (36)	0.834	0.230
Family history of ACL injury	15.2 (33)	24.3 (37)	0.384	17.4 (69)	33.3 (33)	0.121	0.093
• Grandparent	0.0 (33)	0.0 (37)	-	0.0 (69)	3.0 (33)	0.323	0.407
• Parent	0.0 (33)	2.7 (37)	1.000	7.2 (69)	12.1 (33)	0.466	0.531
• Sibling	12.1 (33)	10.8 (37)	1.000	2.9 (69)	6.1 (33)	0.593	0.551
• Child	3.0 (33)	10.8 (37)	0.361	7.2 (69)	6.1 (33)	1.000	0.551
• Other	0.0 (33)	0.0 (37)	-	0.0 (69)	6.1 (33)	0.103	0.164
Family history of joint injury	59.5 (37)	69.2 (39)	0.516	47.2 (72)	72.2 (36)	0.024	0.014
• Parent	21.6 (37)	46.2 (39)	0.031	31.9 (72)	47.2 (36)	0.181	0.018
• Sibling	43.2 (37)	48.7 (39)	0.804	15.3 (72)	44.4 (36)	0.002	0.003
• Child	27.0 (37)	17.9 (39)	0.415	20.8 (72)	19.4 (36)	1.000	0.608

Values are expressed as percentages with the number of participants (n) with available data in parentheses.

¹ SWE-CON vs. SWE -NON, p-values in bold typeset indicate significance (p< 0.050)

² SWE-CON (male + female) vs. SWE-NON (male + female), p-values in bold typeset indicate significance (p< 0.050)

Supplementary Table 5. Genotype effects per patient characteristic in the Swedish cohort

A. Genotype effects *COL5A1* rs2228145 C>T

	C/C (n= 42)	C/T (n= 83)	T/T (n= 61)	p-value
Age (years)	40.2 ± 12.6 (40)	39.9 ± 13.2 (83)	44.0 ± 13.5 (60)	0.145
Sex (% male)	50.0 (21)	43.3 (36)	34.4 (21)	0.197
Height (cm)	174.7 ± 11.0 (38)	172.1 ± 9.0 (78)	171.9 ± 8.6 (55)	0.308
Body mass (kg)	74.1 ± 11.8 (38)	77.3 ± 13.8 (77)	73.3 ± 13.2 (55)	0.782
Body mass index (kg/m ²)	24.0 ± 2.7 (37)	24.6 ± 2.8 (77)	24.7 ± 3.1 (55)	0.536

B. Genotype effects *IL1B* rs16944 C>T

	C/C (n= 78)	C/T (n= 77)	T/T (n= 35)	p-value
Age (years)	42.2 ± 13.2 (77)	39.8 ± 13.3 (75)	42.2 ± 13.5 (35)	0.483
Sex (% male)	50.0 (39)	31.1 (24)	48.6 (17)	0.091
Height (cm)	173.8 ± 9.3 (72)	171.2 ± 9.1 (72)	173.7 ± 9.5 (30)	0.203
Body mass (kg)	75.7 ± 12.2 (70)	71.6 ± 12.8 (72)	73.0 ± 16.0 (31)	0.172
Body mass index (kg/m ²)	24.9 ± 2.8 (70)	24.3 ± 2.7 (72)	24.7 ± 3.2 (30)	0.360

C. Genotype effects *IL6* rs1800795 G>C

	C/C (n= 45)	C/G (n= 107)	G/G (n= 38)	p-value
Age (years)	44.8 ± 12.5 (38)	40.8 ± 13.7 (104)	40.2 ± 12.7 (45)	0.211
Sex (% male)	47.4 (18)	37.4 (40)	46.7 (21)	0.536
Height (cm)	172.7 ± 8.3 (36)	172.3 ± 9.7 (96)	173.0 ± 9.7 (43)	0.927
Body mass (kg)	73.1 ± 11.5 (72)	73.5 ± 14.6 (96)	73.1 ± 12.1 (43)	0.983
Body mass index (kg/m ²)	24.5 ± 2.6 (35)	24.7 ± 3.0 (95)	24.3 ± 2.7 (43)	0.679

D. Genotype effects *IL6R* rs2228145 A>C

	A/A (n = 94)	A/C (n = 76)	C/C (n = 18)	p-value
Age (years)	41.4 ± 13.2 (93)	40.9 ± 14.2 (75)	42.9 ± 8.0 (17)	0.850
Sex (% male)	42.6 (40)	36.8 (28)	55.6 (10)	0.882
Height (cm)	172.2 ± 9.7 (84)	172.5 ± 8.6 (70)	174.6 ± 9.6 (18)	0.610
Body mass (kg)	72.4 ± 11.7 (85)	73.5 ± 14.4 (69)	75.4 ± 12.4 (17)	0.653
Body mass index (kg/m ²)	24.2 ± 2.6 (84)	24.8 ± 3.0 (69)	24.7 ± 2.6 (17)	0.407

Supplementary Table 6. Genotype and minor allele frequency distributions, and p-values for Hardy-Weinberg exact test of the four selected polymorphisms within the South African (SA) and Swedish (SWE) cohort for asymptomatic controls (CON), the anterior cruciate ligament (ACL) rupture group and the ACL subgroup with a noncontact (NON) mechanism.





	n	CON			ACL			SA -NON	P-value ²
		SA-CON	SWE-CON	P-value ¹	SA -ACL	SWE -ACL	P-value ¹		
COL5A1 rs12722 C > T	n	96	109		93	71		48	
	CC	38 (36)	22 (24)	<0.001	41 (38)	23 (18)	0.019	35 (17)	0.021
	CT	49 (47)	43 (47)		45 (42)	47 (36)		54 (26)	
	TT	14 (13)	35 (38)		14 (13)	30 (23)		10 (5)	
	T allele	38 (73)	56 (123)	<0.001	37 (68)	53 (82)	0.003	38 (36)	0.022
	HWE	0.829	0.241		0.824	0.648		0.367	
IL1B rs16944 C > T	n	93	112		93	78		48	
	CC	24 (24)	39 (44)	0.033	27 (25)	44 (34)	0.033	27 (13)	0.095
	CT	47 (46)	41 (46)		52 (48)	40 (31)		44 (21)	
	TT	29 (28)	20 (22)		22 (20)	17 (13)		29 (14)	
	T allele	52 (102)	40 (90)	0.019	47 (88)	37 (57)	0.058	51 (49)	0.033
	HWE	0.549	0.120		0.836	0.224		0.395	
IL6 rs1800795 G > C	n	98	113		98	77		51	
	GG	72 (71)	22 (25)	<0.001	64 (63)	26 (20)	<0.001	67 (34)	<0.001
	GC	26 (25)	59 (67)		31 (30)	52 (40)		27 (14)	
	CC	2 (2)	19 (21)		5 (5)	22 (17)		6 (3)	
	C allele	15 (29)	48 (109)	<0.001	20 (40)	48 (74)	<0.001	20 (20)	<0.001
	HWE	1.000	0.061		0.539	0.821		0.373	
IL6R rs2228145 A > C	n	112	95		76	95		49	
	AA	53 (59)	54 (51)	0.996	46 (35)	58 (55)	0.165	55 (27)	0.886
	AC	37 (41)	34 (32)		46 (35)	39 (37)		43 (21)	
	CC	11 (12)	13 (12)		8 (6)	3 (3)		2 (1)	
	C allele	29 (65)	29 (56)	1.000	31 (47)	23 (43)	0.108	23 (23)	0.256
	HWE	0.082	0.253		0.385	0.599		0.257	

Genotype and allele frequencies are expressed as a percentage with the number of participants (n) in parentheses.



¹ SA vs. SWE cohort (unadjusted p-value), ² SA with non-contact mechanism vs. SWE cohort (unadjusted p-value), P-values in bold typeset indicate significance ($p < 0.050$)

A.


basal levels

**B.****C.**IL-1 β treatment**D.****E.**

IL-6 treatment

**F.****G.****H.**

TNF- α treatment



Supplementary Figure 1: mRNA expression in unstimulated fibroblasts (A, B)

and fibroblasts stimulated with IL-1 β (C, D), IL-6 (E, F) or TNF- α (G, H). mRNA

expression levels of the cytokine-related genes, IL6, IL1B, IL6R, IL1R1 and

TNFRSF1AR in fibroblasts classified in high-risk or low-risk for ACL injuries based on


(A) *IL6* rs1800795 G>C or (B) *IL1B* rs12722 C>T. Data is presented as $2^{-\Delta Ct}$ to

assess gene expression compared to CFL1 (housekeeping gene). Data is presented


as mean with standard deviation (SD). Unpaired two-tailed Student's *t*-test, P-values

in bold represent p-value


A. All participants (males and females),



B. Male participants




C. Female participants




Supplementary Figure 2: Frequency distributions in the South African cohort for the *COL5A1* rs12722 C>T, *IL1B* rs16944 C>T, *IL6* rs1800795 G>C or *IL6R* rs2228145 A>C polymorphisms in the control group (CON; black bars) and the anterior cruciate ligament rupture group (ACL; white bars) for (A) all participants (males and females), (B) the male participants and (C) female participants. The number of participants (n) in each group is in parentheses


A. All participants (males and females)



B. Male participants











C. Female participants



Supplementary Figure 3: Frequency distributions in the Swedish (SWE) cohort for the *COL5A1* rs12722 C>T, *IL1B* rs16944 C>T, *IL6* rs1800795 G>C or *IL6R* rs2228145 A>C polymorphisms in the control group (SWE-CON; black bars) and the non-contact anterior cruciate ligament rupture group (SWE-NON; white bars)

for (A) all participants (males and females), (B) male participants and (C) female participants in the Swedish cohort. The number of participants (n) in each group is in parentheses. P-values in bold typeset indicate significance ($p < 0.050$)



Acknowledgements

The authors would like to thank Prof. Dr. G.J.V.M. van Osch for her contribution to the study design and data interpretation. In addition, we are grateful to Dr. C. D'Alton and Dr. M. Nel for taking the skin biopsies.

This research was funded in part by funds from the National Research Foundation of South Africa grant CPRR 106068 and the University of Cape Town Research Council, South Africa. M.A.M.S and M.P. were financially supported by the European Union funded project RUBICON H2020-MSCA-RISE-2015 – 690850. MR was funded by the Harry Crossley Postdoctoral fellowship. In Sweden, financial support was obtained from the Swedish Scientific Research Council (Grants No. K2011-69X-21877-01-6, K2014-99X-21876-04-4), Västerbotten County Council (Grant No. ALF VLL548501 and Strategic funding VLL-358901; Project No. 7002795).